Biocon Biologics Reaches Landmark Sales Figure As IPO Beckons

Biocon rang in a strong fourth quarter amid signs of a build-up in efforts towards supporting the “independent functioning” of its biosimilars business under subsidiary Biocon Biologics.

Key
BIOCON CONTINUES TO INCH TOWARDS PLANS TO UNLOCK VALUE OF ITS BIOLOGICS BUSINESS • Source: Shutterstock

More from Business

More from Generics Bulletin